Why does FDA send warning letters to aesthetic device manufacturers so often?

FDA has repeatedly cited off-label promotion in this segment, most notably for vaginal rejuvenation and other energy-based device claims that were never reviewed or cleared for those uses, as documented in FDA's 2018 safety communication and related untitled/warning letters. The pattern typically involves marketing a device cleared for one indication (such as general soft-tissue coagulation) for a cosmetic or functional claim it was never studied for. Companies entering aesthetics should map every marketing claim back to the specific cleared indication for use before launch.

How does clearance differ between the US and CE-marked versions of the same aesthetic device?

A device's CE mark under EU MDR reflects the indications and clinical evidence accepted by its EU notified body, which can differ meaningfully from what FDA has cleared for the US market, so the two labels are not interchangeable. Companies expanding into the US after a European launch must verify that US labeling and promotional claims match the FDA-cleared indication for use, not the broader or differently worded EU indication. This mismatch is a common pitfall for companies scaling internationally in aesthetics.

What role do state medical-board scope-of-practice rules play in this market?

Even after FDA clearance, state medical boards independently determine which practitioner types (physicians, nurse practitioners, physician assistants, aestheticians) may operate a given energy-based device and under what supervision level, and these rules vary significantly by state. A manufacturer's commercial strategy, training program, and channel selection must account for this state-by-state variation in addition to the federal clearance, because a device legally marketed nationwide may still be restricted to physician-only use in some jurisdictions.

All terms

Market SegmentsStrategic Landscape

Aesthetic & Energy-Based Devices

Lasers, RF, ultrasound, cryolipolysis, and IPL systems used for medical and cosmetic indications, body contouring, hair removal, skin tightening, vascular lesions.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

Energy-based devices (EBDs) deliver controlled laser, radiofrequency, focused ultrasound, cryogenic, or intense pulsed light energy to tissue for medical (vascular lesions, dermatology, ophthalmology) and cosmetic (hair removal, body contouring, skin tightening) indications. Most are Class II 510(k) devices, though several body-contouring categories required de novo classification.

What the regulation says

Regulated under 21 CFR 878 (general & plastic surgery) and 21 CFR 886 (ophthalmics). FDA has taken multiple enforcement actions against off-label aesthetic claims and has classified several categories (vaginal energy-based devices, 2018) as not approved for cosmetic claims.

What this means in practice

The segment is heavily affected by state medical-board scope-of-practice rules and is a frequent FDA enforcement target for off-label marketing.

Examples

A MedTech clinic uses a pulsed light system to offer patients non-invasive hair removal treatments, targeting melanin in the hair follicles to inhibit future growth.
A healthcare provider employs a radiofrequency-based device to deliver controlled heat to deeper skin layers, stimulating collagen production for improved skin laxity and texture.
A practitioner utilizes a focused ultrasound system for non-surgical body contouring, selectively destroying fat cells beneath the skin without affecting surrounding tissues.

Common pitfalls

•Marketing for vaginal rejuvenation or other indications outside the cleared label, repeat FDA warning-letter target.
•Confusing CE-marked indications with FDA-cleared indications when entering the US.

Frequently asked questions

In the United States they are regulated as medical devices under 21 CFR 878 (general and plastic surgery) or 21 CFR 886 (ophthalmics), not as cosmetics, and most reach market as Class II devices through the 510(k) pathway with a specific cleared indication. A device cleared for hair removal or skin resurfacing cannot lawfully be marketed for indications outside that clearance, even if the underlying energy modality (laser, RF, ultrasound, IPL) is the same across products. Manufacturers and clinics that blur the line between a cleared medical indication and an unapproved cosmetic claim are a recurring target of FDA enforcement.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Regulatory

510(k) Premarket Notification(510(k))

FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.

Regulatory

De Novo Classification Request(De Novo)

Pathway to classify novel low- to moderate-risk devices that lack a predicate.

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 1

Link health: 3 verified· last checked 2026-06-20

FDA·1eCFR·1AdvaMed·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Market Segments0 / 38

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Market Segments
Sources: 3
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

Lasers, RF, ultrasound, cryolipolysis, and IPL systems used for medical and cosmetic indications, body contouring, hair removal, skin tightening, vascular lesions.

·The segment is heavily affected by state medical-board scope-of-practice rules and is a frequent FDA enforcement target for off-label marketing.
·Most are Class II 510(k) devices, though several body-contouring categories required de novo classification.

Remember this

Watch out: Marketing for vaginal rejuvenation or other indications outside the cleared label, repeat FDA warning-letter target.

Related terms

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms